Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey
Background. High blood pressure is a substantial risk factor for cardiovascular disease. Design & Methods. The Physicians' Observational Work on patient Education according to their vascular Risk (POWER) survey was an open-label investigation of eprosartan-based therapy (EBT) for control of...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2013/165789 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562641672863744 |
|---|---|
| author | Guy De Backer Robert J. Petrella Assen R. Goudev Ghazi Ahmad Radaideh Andrzej Rynkiewicz Atul Pathak |
| author_facet | Guy De Backer Robert J. Petrella Assen R. Goudev Ghazi Ahmad Radaideh Andrzej Rynkiewicz Atul Pathak |
| author_sort | Guy De Backer |
| collection | DOAJ |
| description | Background. High blood pressure is a substantial risk factor for cardiovascular disease. Design & Methods. The Physicians' Observational Work on patient Education according to their vascular Risk (POWER) survey was an open-label investigation of eprosartan-based therapy (EBT) for control of high blood pressure in primary care centers in 16 countries. A prespecified element of this research was appraisal of the impact of EBT on estimated 10-year risk of a fatal cardiovascular event as determined by the Systematic Coronary Risk Evaluation (SCORE) model. Results. SCORE estimates of CVD risk were obtained at baseline from 12,718 patients in 15 countries (6504 men) and from 9577 patients at 6 months. During EBT mean (±SD) systolic/diastolic blood pressures declined from 160.2 ± 13.7/94.1 ± 9.1 mmHg to 134.5 ± 11.2/81.4 ± 7.4 mmHg. This was accompanied by a 38% reduction in mean SCORE-estimated CVD risk and an improvement in SCORE risk classification of one category or more in 3506 patients (36.6%). Conclusion. Experience in POWER affirms that (a) effective pharmacological control of blood pressure is feasible in the primary care setting and is accompanied by a reduction in total CVD risk and (b) the SCORE instrument is effective in this setting for the monitoring of total CVD risk. |
| format | Article |
| id | doaj-art-daa8f83888534ed08a9a9315d18279db |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-daa8f83888534ed08a9a9315d18279db2025-02-03T01:22:12ZengWileyInternational Journal of Hypertension2090-03842090-03922013-01-01201310.1155/2013/165789165789Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER SurveyGuy De Backer0Robert J. Petrella1Assen R. Goudev2Ghazi Ahmad Radaideh3Andrzej Rynkiewicz4Atul Pathak5Department of Public Health, Ghent University Hospital, DePintelaan 185, 9000 Ghent, BelgiumDepartment of Family Medicine and Cardiology, Lawson Health Research Institute, 801 Commissioners Road East, University of Western Ontario, ON, N6C 5J1, CanadaPreventive Cardiology Clinic, Department of Internal Medicine, Medical University of Sofia, Sofia 1431, BulgariaRashid Hospital, P.O. Box 4545, Oud Metha Road, Dubai, UAEDepartment of Cardiology, Medical University of Gdañsk, M. Skłodowskiej-Curie 3a Street, 80-210 Gdañsk, PolandClinical Pharmacology Service, INSERM Unit 1048, Faculty of Medicine, University Hospital Toulouse, 1073 Toulouse, FranceBackground. High blood pressure is a substantial risk factor for cardiovascular disease. Design & Methods. The Physicians' Observational Work on patient Education according to their vascular Risk (POWER) survey was an open-label investigation of eprosartan-based therapy (EBT) for control of high blood pressure in primary care centers in 16 countries. A prespecified element of this research was appraisal of the impact of EBT on estimated 10-year risk of a fatal cardiovascular event as determined by the Systematic Coronary Risk Evaluation (SCORE) model. Results. SCORE estimates of CVD risk were obtained at baseline from 12,718 patients in 15 countries (6504 men) and from 9577 patients at 6 months. During EBT mean (±SD) systolic/diastolic blood pressures declined from 160.2 ± 13.7/94.1 ± 9.1 mmHg to 134.5 ± 11.2/81.4 ± 7.4 mmHg. This was accompanied by a 38% reduction in mean SCORE-estimated CVD risk and an improvement in SCORE risk classification of one category or more in 3506 patients (36.6%). Conclusion. Experience in POWER affirms that (a) effective pharmacological control of blood pressure is feasible in the primary care setting and is accompanied by a reduction in total CVD risk and (b) the SCORE instrument is effective in this setting for the monitoring of total CVD risk.http://dx.doi.org/10.1155/2013/165789 |
| spellingShingle | Guy De Backer Robert J. Petrella Assen R. Goudev Ghazi Ahmad Radaideh Andrzej Rynkiewicz Atul Pathak Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey International Journal of Hypertension |
| title | Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey |
| title_full | Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey |
| title_fullStr | Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey |
| title_full_unstemmed | Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey |
| title_short | Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey |
| title_sort | effect of antihypertensive therapy on score estimated total cardiovascular risk results from an open label multinational investigation the power survey |
| url | http://dx.doi.org/10.1155/2013/165789 |
| work_keys_str_mv | AT guydebacker effectofantihypertensivetherapyonscoreestimatedtotalcardiovascularriskresultsfromanopenlabelmultinationalinvestigationthepowersurvey AT robertjpetrella effectofantihypertensivetherapyonscoreestimatedtotalcardiovascularriskresultsfromanopenlabelmultinationalinvestigationthepowersurvey AT assenrgoudev effectofantihypertensivetherapyonscoreestimatedtotalcardiovascularriskresultsfromanopenlabelmultinationalinvestigationthepowersurvey AT ghaziahmadradaideh effectofantihypertensivetherapyonscoreestimatedtotalcardiovascularriskresultsfromanopenlabelmultinationalinvestigationthepowersurvey AT andrzejrynkiewicz effectofantihypertensivetherapyonscoreestimatedtotalcardiovascularriskresultsfromanopenlabelmultinationalinvestigationthepowersurvey AT atulpathak effectofantihypertensivetherapyonscoreestimatedtotalcardiovascularriskresultsfromanopenlabelmultinationalinvestigationthepowersurvey |